Published in Rheumatol Int on July 29, 2011
[Recommendations of the German Society for Rheumatology on the perioperative approach under therapy with DMARDs and biologicals in inflammatory rheumatic diseases]. Z Rheumatol (2014) 0.83
Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement. J Rheumatol (2013) 0.80
Renal and Gastrointestinal Considerations in Joint Replacement Surgery. J Nat Sci (2015) 0.79
Perioperative management of patients with rheumatic diseases. Open Rheumatol J (2013) 0.79
Management of hip involvement in ankylosing spondylitis. Clin Rheumatol (2013) 0.76
Perioperative management of drugs commonly used in patients with rheumatic diseases: a review. Clinics (Sao Paulo) (2017) 0.75
Pilot study for the registry of complications in rheumatic diseases from the German Society of Surgery (DGORh): evaluation of methods and data from the first 1000 patients. BMJ Open (2017) 0.75
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum (2008) 9.94
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum (2005) 8.47
Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum (2002) 4.69
Risk factors for prosthetic joint infection: case-control study. Clin Infect Dis (1998) 3.96
Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) (2005) 3.56
Predictors of infection in rheumatoid arthritis. Arthritis Rheum (2002) 3.47
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum (2007) 3.38
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) (2010) 3.04
Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum (2006) 3.03
Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol (2007) 2.73
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis (2007) 2.53
The Swedish Knee Arthroplasty Register 1975-1997: an update with special emphasis on 41,223 knees operated on in 1988-1997. Acta Orthop Scand (2001) 2.49
Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum (2007) 2.46
Infection as a complication of total knee-replacement arthroplasty. Risk factors and treatment in sixty-seven cases. J Bone Joint Surg Am (1990) 2.45
Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol (2005) 2.40
Risk factors for infection after knee arthroplasty. A register-based analysis of 43,149 cases. J Bone Joint Surg Am (2009) 2.21
Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis (2010) 2.04
Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatology (Oxford) (2009) 1.90
Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol (2001) 1.86
Declining use of orthopedic surgery in patients with rheumatoid arthritis? Results of a long-term, population-based assessment. Arthritis Rheum (2003) 1.83
Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum (2008) 1.79
Polyarticular septic arthritis. Medicine (Baltimore) (1993) 1.78
Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum (1996) 1.73
All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis (2007) 1.68
Pyarthrosis in patients with rheumatoid arthritis: a report of 13 cases and a review of the literature from the past 40 years. Am J Med (1990) 1.58
Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum (2006) 1.57
Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken) (2010) 1.55
Risk of revision for infection in primary total hip and knee arthroplasty in patients with rheumatoid arthritis compared with osteoarthritis: a prospective, population-based study on 108,786 hip and knee joint arthroplasties from the Norwegian Arthroplasty Register. Arthritis Care Res (Hoboken) (2010) 1.55
The role of tumor necrosis factor in health and disease. J Rheumatol Suppl (1999) 1.54
Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease. J Gastrointest Surg (2010) 1.54
The infected knee arthroplasty. A 6-year follow-up of 357 cases. Acta Orthop Scand (1991) 1.51
Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine (2009) 1.49
Progression of radiographic joint damage in different eras: trends towards milder disease in rheumatoid arthritis are attributable to improved treatment. Ann Rheum Dis (2006) 1.44
Interleukin-6, procalcitonin and TNF-alpha: markers of peri-prosthetic infection following total joint replacement. J Bone Joint Surg Br (2007) 1.40
Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983-2007. Ann Rheum Dis (2009) 1.36
Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis (2010) 1.34
The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther (2004) 1.33
Perioperative factors associated with septic arthritis after arthroplasty. Prospective multicenter study of 362 knee and 2,651 hip operations. Acta Orthop Scand (1992) 1.32
A population based assessment of the use of orthopedic surgery in patients with rheumatoid arthritis. J Rheumatol (2002) 1.30
BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) (2010) 1.30
Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int (2004) 1.29
Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol (2004) 1.27
Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev (2008) 1.20
Tumor necrosis factor and wound healing. Ann Surg (1990) 1.19
Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing. Pharmacotherapy (2005) 1.15
Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis (2005) 1.14
Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol (2007) 1.06
Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Dis Colon Rectum (2003) 1.03
The place of methotrexate perioperatively in elective orthopedic surgeries in patients with rheumatoid arthritis. Clin Rheumatol (2008) 1.03
Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Société Française de Rhumatologie, SFR). Joint Bone Spine (2005) 0.98
Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study. Arthritis Res Ther (2010) 0.96
Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol (2010) 0.96
Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis (2005) 0.93
The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. Arthritis Rheum (2007) 0.92
UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register. Rheumatology (Oxford) (2006) 0.90
Rheumatoid arthritis is the major risk factor for septic arthritis in rheumatological settings. Autoimmun Rev (2008) 0.90
Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis. Ann Rheum Dis (2006) 0.85
A systematic review on the optimum management of the use of methotrexate in rheumatoid arthritis patients in the perioperative period to minimize perioperative morbidity and maintain disease control. Clin Exp Rheumatol (2009) 0.85
Infection versus disease activity in rheumatoid arthritis: eight years' experience. South Med J (1986) 0.83
Tumour necrosis factor: implications for surgical patients. ANZ J Surg (2006) 0.80
Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis. Rheumatol Int (2006) 0.76
BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) (2009) 2.37
Acute systemic lupus erythematosus on the acute medical take: are we missing anything? Clin Med (2011) 2.04
10-minute consultation: chronic low back pain. BMJ (2003) 1.95
BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford) (2010) 1.79
In search of a good death: Human Rights Act 1998 imposes an obligation to facilitate a good death. BMJ (2003) 0.90
Catch me if you can: a national survey of rheumatologists and obstetricians on the use of DMARDs during pregnancy. Rheumatol Int (2012) 0.84
Association analysis of TNFR2, VDR, A2M, GSTT1, GSTM1, and ACE genes with rheumatoid arthritis in South Asians and Caucasians of East Midlands in the United Kingdom. Rheumatol Int (2010) 0.82
Update on biologic therapies in ankylosing spondylitis: a literature review. Int J Rheum Dis (2012) 0.79
Rheumatology nurse practitioners' perceptions of their role. Musculoskeletal Care (2006) 0.79
End of life decisions. BMJ (2005) 0.78
Association of PTPN22 with rheumatoid arthritis among South Asians in the UK. J Rheumatol (2007) 0.78
Is epidural injection of steroids effective for low back pain? BMJ (2004) 0.77
Referring GMC decisions to the High Court. BMJ (2005) 0.75
Charges of corporate manslaughter in the NHS. BMJ (2006) 0.75
Medical experts, the law and professional regulation. J R Soc Med (2006) 0.75
Consultant careers. Clin Med (2002) 0.75
Polyarthralgia. BMJ (2003) 0.75
A systematic review of the influence of anti-TNF on infection rates in patients with rheumatoid arthritis. Rev Bras Reumatol (2014) 0.75
Connective tissue diseases. Practitioner (2004) 0.75